Article: Ascent Therapeutics Achieves Preclinical in vivo Proof-of-Principle with Novel Pepducin™ GPCR Modulator Platform and Strengthens Senior Management Team.

Ascent Therapeutics announced that the Company has demonstrated efficacy in preclinical models in two Pepducin™ projects. One of the projects targets CXCR4, a key regulator of stem cell and inflammatory cell homeostasis. A second project has yielded the first potent Pepducin agonists for an undisclosed cardiovascular target. The Company also announced that Kenneth Carlson, PhD has joined the senior management team as Senior Director, Head of Biology and that the Company will be presenting at multiple business development events in the coming months.

"These studies demonstrated Pepducin activity in the CXCR4 compounds that is equal or better than the current ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!